To biologically validate the results described, we investigated the method's performance in assessing the EV‐EGFR status in a separate cohort of 20 NSCLC patients stratified as EGFR WT both in tissue biopsy and cfDNA (Fig. S3). Here, EGFR is linked to non-small cell lung carcinoma.